Drugs that boost a brain glutamate transporter to reduce alcohol dependence
Official title: Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies
Funded at University of Toledo Health Sci Campus · NIH-11098521 · Data updated 2026-11-12
Testing new compounds that increase a brain protein that clears glutamate to help people with alcohol dependence drink less and avoid relapse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project start | September 1, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $416,030 |
| NIH project number | 5R01AA029674-04 |
| Project ID | NIH-11098521 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with alcohol dependence or heavy, uncontrolled alcohol use who are seeking new treatment options would be the likely candidates for future clinical trials based on this work.
✕Less likely to help
People without alcohol dependence or whose drinking is driven primarily by non-glutamate mechanisms or social factors may not benefit from this approach.
What this research studies
From a patient perspective: researchers are developing novel compounds that raise levels of GLT-1, a brain protein that helps clear excess glutamate linked to alcohol craving and relapse. They will test these compounds and a non-antibiotic β-lactam in lab models to measure drinking-related behaviors, brain target engagement, drug levels, and inflammatory markers. The team will use pharmacokinetic and pharmacodynamic studies and look for biomarkers that indicate the drug is hitting its target and changing brain chemistry. Findings will be used to pick dosing and biomarkers for future human clinical trials if results look promising.
Why it matters
Potential benefit: If successful, this work could lead to new medications that reduce craving, heavy drinking, and relapse in people with alcohol dependence.
How similar studies have gone: Preclinical studies with β-lactam antibiotics such as ceftriaxone have reduced alcohol intake and relapse in alcohol-preferring rats, but clinical testing in people is limited and these new compounds aim to avoid antibiotic effects.
Where this research is happening
-
University of Toledo Health Sci Campus
Toledo, United States Active
Researchers
- Principal investigator: Sari, Youssef — University of Toledo Health Sci Campus
- Study coordinator: Sari, Youssef
Related research
Other NIH-funded projects on the same topics.
-
Medial Prefrontal Cortex and Alcohol Relapse in Humans
A study aims to understand brain factors in relapse to drinking alcohol after abstinence, focusing on the medial prefrontal cortex and blood-brain barrier changes in adults with alcohol use disorder.
-
New GLT-1 Activators to Help People with Alcohol Dependence
A new preclinical study tests novel drugs that boost a brain transporter to reduce drinking and relapse in alcohol-related conditions.
-
Activation of PSTN CRF neurons and their role in alcohol drinking
A study in mice explores how activating specific brain neurons in the parasubthalamic nucleus affects patterns of drinking and the motivation behind alcohol use.
-
Mapping immune-related gene changes in the brains of people with alcohol dependence
This project maps where and which brain cells show immune-related gene changes in people with alcohol dependence to point toward new treatment targets.
-
Targeting brain support cells to curb heavy drinking and brain inflammation
This project is testing whether lowering a specific enzyme in brain support cells (astrocytes) can curb heavy drinking and brain inflammation for people with alcohol dependence.
-
Frontal brain changes linked to alcohol relapse
This work looks at how changes in a frontal brain area and blood–brain barrier problems may lead to relapse in adults with alcohol use disorder.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.